openPR Logo
Press release

Zanamivir Market Size, Trends, Growth Analysis, and Forecast | Valuates Reports

01-21-2025 02:07 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Valuates Reports

Zanamivir Market Size

The global market for Zanamivir was estimated to be worth US$ 10 million in 2023 and is forecast to a readjusted size of US$ 14 million by 2030 with a CAGR of 4.5% during the forecast period 2024-2030.

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-3U10467/Global_Zanamivir_Market_Insights_Forecast_to_2028

This report aims to provide a comprehensive presentation of the global market for Zanamivir, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Zanamivir by region & country, by Type, and by Application.

By Type
• Purity 97%
• Purity 98%
• Purity 99%

By Application
• Pharmaceutical
• Scientific Research

Key Companies
Merck, Tokyo Chemical Industry (TCI), DC Chemicals, Hairui Chemical, Key Organics, BioCrick, BLD Pharmatech, BOC Sciences, CSNpharm, Selleck Chemicals, Glentham Life Sciences

View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-3U10467/global-zanamivir

Please reach us at sales@valuates.com

Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Zanamivir Market Size, Trends, Growth Analysis, and Forecast | Valuates Reports here

News-ID: 3825548 • Views:

More Releases from Valuates Reports

Software-Defined Everything (SDE) Market Size, Trends & Forecasts | Valuates Rep …
Software-Defined Everything (SDE) Market Software-defined everything (SDE) is an umbrella term for a number of technologies that are helping redefine IT. Currently, this group of technologies encompasses software-defined networking (SDN), software-defined storage (SDS), and software-defined data centers (SDDC). Each approach aims to abstract the operating environment from physical infrastructure, while automating the processes that manage the infrastructure. By freeing businesses from proprietary hardware and simplifying the provisioning and management of IT
AI Server Market Size, Trends & Forecasts | Valuates Reports
AI Server Market Size The global AI Server market is projected to grow from US$ 31720 million in 2024 to US$ 78810 million by 2030, at a Compound Annual Growth Rate (CAGR) of 16.4% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-24S15068/Global_AI_Server_Market_Research_Report_2023?utm_source=openpr&utm_medium=referral&utm_campaign=openpr_referral Major Trends The global AI server market is driven by several key factors, including the rising adoption of artificial intelligence across various industries, advancements in AI technology, and the increasing need for
Precision Air Conditioner Market Size, Trends & Forecasts | Valuates Reports
Precision Air Conditioner Market Size The global Precision Air Conditioner revenue was US$ 4926.8 million in 2022 and is forecast to a readjusted size of US$ 7815.6 million by 2029 with a CAGR of 6.8% during the forecast period (2023-2029). Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-38A15722/Global_and_India_Precision_Air_Conditioner_Market_Report_Forecast_2023_2029?utm_source=openpr&utm_medium=referral&utm_campaign=openpr_referral The key precision air conditioning manufacturers are Vertiv, Stulz, Daikin etc. Top 3 companies occupied about 30% market share. China is the largest market, with a share about 35%,
Non-Segregated Phase Bus Duct Market Set to Surge - Key Insights You Must Know
Non-Segregated Phase Bus Duct Market Non-segregated phase bus is an assembly of bus conductors with associated connections, joints, and insulating supports confined within a metal enclosure without interphase barriers. The global Non-Segregated Phase Bus Duct market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-21G10197/Global_Non_Segregated_Phase_Bus_Duct_Market_Insights_Forecast_to_2028?utm_source=openpr&utm_medium=referral&utm_campaign=openpr_referral North American market for Non-Segregated Phase Bus Duct

All 5 Releases


More Releases for Zanamivir

Influenza Medication Market Size, Share, and Forecast 2023-2028 - by Types (Zana …
The Global Influenza Medication Market Report 2023 by 𝐏𝐫𝐚𝐠𝐦𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 provides a comprehensive overview of the market's latest trends, size, regulations, key players, and strategies. The report offers valuable insights into the market's sales and revenue, product type, applications, regions, and leading players. It also covers key players and competitor analysis, providing a comprehensive understanding of the market's commercial landscape. The report is useful for gaining insights and understanding the
Best Report on Influenza Medication Market with Segment (Zanamivir, Oseltamivir …
Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. Seasonal outbreak of influenza primarily occurs in winter.
Influenza Vaccine Market : New Study Offers Insights for 2019 | Zanamivir, Oselt …
Global Influenza Medication Market: Snapshot Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. Seasonal outbreak of influenza
Influenza Drugs and Vaccines Trends, Status, Sales, Revenue, Price and Gross Mar …
Global Influenza Drugs and Vaccines Market: WiseGuyReports.com adds “Influenza Drugs and Vaccines Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. WiseGuyReports.Com Publish a New Market Research Report On – Executive Summary: A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Influenza Market on the basis of Segment Type
The Future Growth of Global Influenza Drugs and Vaccines Market - By Drugs (Zana …
"The Report Global Influenza Drugs and Vaccines Market - By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis By Region, By Country: Opportunities and Forecast (2016-2021) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan) provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" A comprehensive research report created through extensive
Global Zanamivir Market 2016 - GlaxoSmithKline, Simcere, Lunan Pharmaceutical
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor